NEWYORK (GenomeWeb) – Sophia Genetics and diagnostic developer Devyser have agreed to combine their respective products to provide next-generation sequencing-based testing solutions for hereditary and inherited diseases to routine diagnostics laboratories.
Specifically, the partners have agreed to use the Sophia Data Driven Medicine (Sophia DDM) platform to analyze data from diagnostic kits sold by Devyser for hereditary breast cancer and cystic fibrosis testing. Devyser's BRCA kit covers all coding regions, promoter, and exon-intron boundaries of BRCA1 and BRCA2 and can be used to detect both germline and somatic mutations in both genes. It features Devyser's multiplex PCR primer chemistry, which supports overlapping primer design within a single tube, helping to minimize the risk of sample mix-up and cross-contamination. The company's cystic fibrosis kit covers all CTFR mutations present in coding regions, intron/exon boundaries and promoter regions as well as relevant deep intronic sequences and large structural deletions.
The combined offering will be available immediately to Devyser's distribution network and to the roughly 170 member hospitals that use Sophia DDM, the partners said. Customers will be able to "leverage Devyser's reliable and easy-to-use products to obtain clinical grade results on Sophia DDM," Jurgi Camblong, Sophia's CEO and founder, said in a statement. It will help laboratories "unlock the power of NGS with record-low turnaround time, improving both diagnostics and treatment options for patients."
Financial and other terms of the agreement were not disclosed.
Earlier this year, Sophia signed a similar agreement with Multiplicom that allowed it to bundle Sophia DDM with that company's molecular diagnostic kits. Multiplicom develops and commercializes molecular diagnostic assays based on its Multiplex Amplification of Specific Targets for Resequencing technology for cancer testing, genetic disease predisposition, and congenital defects in pregnancy.